Start Date
August 31, 2018
Primary Completion Date
January 31, 2019
Study Completion Date
December 28, 2021
avelumab
Fully human anti-programmed death-ligand 1 (PD-L1) immunoglobulin (Ig)G1 lambda monoclonal antibody
bevacizumab
Recombinant human anti-vascular endothelial growth factor (VEGF) IgG1 monoclonal antibody
capecitabine
5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
cetuximab
Recombinant human/mouse chimeric anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody
Cyclophosphamide
2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
5-Fluorouracil (5-FU)
5-fluoro-2,4 (1H,3H)-pyrimidinedione
fulvestrant
7-alpha-\[9-(4,4,5,5,5-pentafluoropentylsulphinyl) nonyl\]estra-1,3,5-(10)- triene-3,17-beta-diol
leucovorin
Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
nab paclitaxel
5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
nivolumab
Human anti-programmed cell death protein 1 (PD-1) IgG4 kappa monoclonal antibody
Lovaza
Omega-3-acid ethyl esters
oxaliplatin
cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum
Stereotactic Body Radiation Therapy
(SBRT)
ALT-803
recombinant human super agonist interleukin-15 (IL-15) complex
ETBX-011
adenovirus serotype-5 \[Ad5\] \[E1-, E2b-\]-carcinoembryonic antigen \[CEA\] vaccine
ETBX-021
Ad5 \[E1-, E2b-\]-human epidermal growth factor receptor 2 \[HER2\] vaccine
ETBX-051
Ad5 \[E1-, E2b-\]-Brachyury vaccine
ETBX-061
Ad5 \[E1-, E2b-\]-mucin 1 \[MUC1\] vaccine
GI-4000
RAS yeast vaccine
GI-6207
CEA yeast vaccine
GI-6301
Brachyury yeast vaccine
haNK
NK-92 \[CD16.158V, ER IL-2\], Suspension for Intravenous \[IV\] Infusion
Lead Sponsor
ImmunityBio, Inc.
INDUSTRY